Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.01; Reports Implementation of Austerity Measures

August 15, 2016 5:08 PM EDT
Get Alerts HEB Hot Sheet
Trade HEB Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Hemispherx Biopharma (NYSE: HEB) reported Q2 EPS of ($0.01), versus ($0.04) reported last year.

Hemispherx Biopharma has made changes to its senior management team and has implemented austerity measures which included the reduction of executive compensation and elimination of non-essential contractors and personnel. These measures have resulted in a significant reduction in costs and expenses. The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.

For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Hot Corp. News, Management Changes

Related Entities


Add Your Comment